In colon cancer, m6A modification genes in exosomes significantly influence the TME, where a low m6A-related exosomal gene score (MREGS) is associated with enhanced survival, immune activation, and a better response to anti-PD-L1 immunotherapy, while a high MREGS correlates with increased stromal activation, heightened innate immune cell activity, and poorer survival outcomes [99]. The gene discussed is CD274; the disease is colonic neoplasm.